|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2008-8-7
|
|
pubmed:abstractText |
Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy. We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N(4)-(2,3-dimethyl-2H-indazol-6-yl)-N(4)-methyl-N(2)-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell cancer and other solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1520-4804
|
|
pubmed:author |
pubmed-author:AlfanoNoraN,
pubmed-author:CheungMuiM,
pubmed-author:CrosbyRenae MRM,
pubmed-author:Davis-WardRonda GRG,
pubmed-author:EpperlyAndrea HAH,
pubmed-author:HarrisPhilip APA,
pubmed-author:HinkleKevin WKW,
pubmed-author:HunterRobert NRN3rd,
pubmed-author:JohnsonJennifer HJH,
pubmed-author:KnickVictoria BVB,
pubmed-author:KumarRakeshR,
pubmed-author:LaudemanChristopher PCP,
pubmed-author:LuttrellDeirdre KDK,
pubmed-author:MookRobert ARA,
pubmed-author:NolteRobert TRT,
pubmed-author:RudolphSharon KSK,
pubmed-author:StaffordJeffrey AJA,
pubmed-author:SzewczykJerzy RJR,
pubmed-author:TruesdaleAnne TAT,
pubmed-author:VealJames MJM,
pubmed-author:WangLipingL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
14
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4632-40
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18620382-Animals,
pubmed-meshheading:18620382-Cells, Cultured,
pubmed-meshheading:18620382-Crystallography, X-Ray,
pubmed-meshheading:18620382-Cytochrome P-450 Enzyme System,
pubmed-meshheading:18620382-Humans,
pubmed-meshheading:18620382-Isoenzymes,
pubmed-meshheading:18620382-Mice,
pubmed-meshheading:18620382-Models, Molecular,
pubmed-meshheading:18620382-Molecular Structure,
pubmed-meshheading:18620382-Neoplasms,
pubmed-meshheading:18620382-Protein Kinase Inhibitors,
pubmed-meshheading:18620382-Pyrimidines,
pubmed-meshheading:18620382-Receptors, Vascular Endothelial Growth Factor,
pubmed-meshheading:18620382-Sulfonamides,
pubmed-meshheading:18620382-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.
|
|
pubmed:affiliation |
GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709, USA. philip.a.harris@gsk.com
|
|
pubmed:publicationType |
Journal Article
|
